Angioimmunoblastic T-Cell Lymphoma with Exuberant CD30-Positive Follicular Dendritic Cell Proliferation in a SARS-CoV-2 Patient: The Role of Mutational Analysis to Exclude an Associated Follicular Dendritic Cell Sarcoma

Int J Mol Sci. 2022 Aug 19;23(16):9349. doi: 10.3390/ijms23169349.

Abstract

Follicular dendritic cell (FDC) proliferation in angioimmunoblastic T-cell lymphoma (AITL) is still not well defined, challenging the accurate differential diagnosis between the AITL with expanded follicular dendritic cell meshwork and the combined AITL and follicular dendritic cell sarcoma (FDCS). Herein, we reported the case of a 58-year-old male with coexisting SARS-CoV-2 infection and AITL with an exuberant CD30-positive FDC proliferation, in which genetic analysis identified mutations of genes commonly involved in AITL but not in FDC sarcoma (i.e., RHOA, TET2, DNMT3A, and IDH2), thus supporting the reactive nature of the CD30-positive FDC expansion.

Keywords: AITL; CD30 expression; SARS-CoV-2 infection; follicular dendritic cell proliferation.

Publication types

  • Case Reports

MeSH terms

  • COVID-19*
  • Cell Proliferation
  • Dendritic Cell Sarcoma, Follicular* / diagnosis
  • Dendritic Cell Sarcoma, Follicular* / genetics
  • Dendritic Cell Sarcoma, Follicular* / pathology
  • Dendritic Cells, Follicular / pathology
  • Humans
  • Immunoblastic Lymphadenopathy* / diagnosis
  • Immunoblastic Lymphadenopathy* / genetics
  • Immunoblastic Lymphadenopathy* / pathology
  • Ki-1 Antigen / genetics
  • Lymphoma, T-Cell* / diagnosis
  • Lymphoma, T-Cell* / genetics
  • Lymphoma, T-Cell* / pathology
  • Male
  • Middle Aged
  • SARS-CoV-2

Substances

  • Ki-1 Antigen

Grants and funding

This research received no external funding.